XM n’offre pas ses services aux résidents des États-Unis d’Amérique.

U
U

UCB

Actualités

Reuters - Il y a 3 jours

Immunovant shares surge as early antibody treatment data beats expectations

UPDATE 3-Immunovant shares surge as early antibody treatment data beats expectations Adds analyst comment in paragraph 9, graphic, updates shares By Bhanvi Satija Sept 26 (Reuters) - Shares of Immunovant IMVT.O more than doubled on Tuesday after early-stage data from its experimental antibody treatment exceeded analysts' expectations. The drug developer, whose shares hit a more than two-and-a-half year high of $41.72, was set to add nearly $3 billion to its market capitalization if gains hold.
U
Reuters - Il y a 3 jours

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Sept 26 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. AIR FRANCE-KLM AIRF.PA /AIRBUS AIR.PA The European airline company said on Monday it will order 50 Airbus A350 long-haul jets and purchase rights for an additional 40 aircraft.
A
U
A
U
Reuters - Il y a 3 jours

UCB Announces Approval Of Rystiggo[®] (Rozanolixizumab) And Zilbrysq[®] (Zilucoplan) For Treatment Of Adult Patients With Generalised Myasthenia Gravis In Japan

BRIEF-UCB Announces Approval Of Rystiggo[®] (Rozanolixizumab) And Zilbrysq[®] (Zilucoplan) For Treatment Of Adult Patients With Generalised Myasthenia Gravis In Japan Sept 25 (Reuters) - Ucb SA UCB.BR : UCB ANNOUNCES APPROVAL OF RYSTIGGO[®] (ROZANOLIXIZUMAB) AND ZILBRYSQ[®] (ZILUCOPLAN) FOR THE TREATMENT OF ADULT PATIENTS WITH GENERALIZED MYAST
U
Reuters - Il y a 1 semaine

UCB Provides Update On U.S. Regulatory Review of Bimekizumab

BRIEF-UCB Provides Update On U.S. Regulatory Review of Bimekizumab Sept 20 - UCB.BR : UCB HAS RECEIVED THE ESTABLISHMENT INSPECTION REPORT (EIR) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOLLOWING THE PRE-LICENSE INSPECTION CONDUCTED IN APRIL 2023 THE FDA HAS CONCLUDED THAT THIS INSPECTION IS SUCCESSFULLY CLOSED FDA IS CONTINUING ITS REVIEW
U
Reuters - Il y a 2 semaines

UCB: CHMP Positive Opinion Of Zilucoplan For Treatment Of Adults With Generalized Myasthenia Gravis In Europe

BRIEF-UCB: CHMP Positive Opinion Of Zilucoplan For Treatment Of Adults With Generalized Myasthenia Gravis In Europe Sept 15 (Reuters) - Ucb SA UCB.BR : UCB RECEIVES CHMP POSITIVE OPINION OF ZILUCOPLAN FOR THE TREATMENT OF ADULTS WITH GENERALIZED MYASTHENIA GRAVIS IN EUROPE IF APPROVED BY THE EUROPEAN COMMISSION ZILUCOPLAN WILL BE THE FIRST ONCE-DAILY SUBCUTANEOUS (SC) TARGETED PEPTIDE INHIBITOR OF COMPLEMENT COMPONENT 5 (C5 INHIBITOR) AND THE ONLY GMG-TARGETED THERAPY FOR SELF-ADMINISTRATION BY
U
Reuters - Il y a 3 semaines

DB ups UCB to 'buy' on results, potential FDA approval

BUZZ-DB ups UCB to 'buy' on results, potential FDA approval ** Deutsche Bank raises UCB UCB.BR to "buy" from "hold", following the Belgian drugmaker's solid H1 results and citing potential U.S. FDA approval of a drug ** The broker says the upgrade comes also from a potential approval of Bimzelx for psoriasis in Q3 by the U.S. Food and Drug Administ
U
Reuters - Il y a 3 semaines

Brooks MacDonald Group, Genmab, Swisscom

EUROPE RESEARCH ROUNDUP- Brooks MacDonald Group, Genmab, Swisscom Sept 6 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Brooks MacDonald Group, Genmab and Swisscom, on Wednesday. HIGHLIGHTS * Brooks MacDonald Group Plc BRK.L : RBC cuts target price to 2,100p from 2,150p * Genmab A/S GMAB.CO : RBC cuts to sector perform from outperform * H&M HMb.ST : Bernstein raises target price to SEK 130 from SEK 125 * Swisscom AG SCMN.S : Beren
A
H
H
H
I
I
S
S
U
H
A
N
Reuters - Il y a 2 mois

Beiersdorf AG, Galenica, L'Oreal

EUROPE RESEARCH ROUNDUP-Beiersdorf AG, Galenica, L'Oreal Aug 15 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Beiersdorf AG, Galenica and L'Oreal, on Tuesday. HIGHLIGHTS * Beiersdorf AG BEIG.DE : Bernstein raises to outperform from market perform * Danone DANO.PA : Bernstein cuts to underperform from market perform * Galenica GALE.S : UBS raises to buy from neutral * L'Oreal OREP.PA : Bernstein raises to outperform from market pe
A
A
A
B
B
C
D
D
D
D
H
H
L
M
N
P
P
R
S
S
T
U
S
Reuters - Il y a 2 mois

Ucb H1 Revenue Reached € 2.6 Billion

BRIEF-Ucb H1 Revenue Reached € 2.6 Billion July 27 (Reuters) - Ucb SA UCB.BR : UCB SA - UCB HALF-YEAR REPORT 2023 UCB SA - H1 REVENUE REACHED € 2.6 BILLION (-11%; -13% CER1), NET SALES WERE € 2.4 BILLION (-12%; -14% CER1) UCB SA - H1 UNDERLYING PROFITABILITY (ADJUSTED. EBITDA2) WAS € 801 MILLION (-2%; -9% CER1), 31% OF REVENUE UCB SA - FINANCIAL GUIDANCE FOR 2023 CONFIRMED: REVENUE EXPECTED TO REACH € 5.15 - 5.35 BILLION, ADJUSTED EBITDA2 22.5 - 23.5% OF REVENUE, CORE EPS3 OF € 3.40
U
Reuters - Il y a 2 mois

Aston Martin, Equinor ASA, Softcat

EUROPE RESEARCH ROUNDUP-Aston Martin, Equinor ASA, Softcat July 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Aston Martin, Equinor ASA and Softcat, on Wednesday. HIGHLIGHTS * Aston Martin AML.L : Goldman Sachs raises to buy from neutral * Computacenter Plc CCC.L : JP Morgan initiates coverage with overweight rating * Equinor ASA EQNR.OL : Berenberg cuts to sell from hold * Evonik Industries AG EVKn.DE : Morgan Stanley cuts to
A
B
B
B
B
C
D
E
E
E
E
F
G
G
I
K
N
N
O
O
R
R
S
T
U
G
I
Reuters - Il y a 2 mois

UCB Announces EU Regulatory Filing For Bimekizumab

BRIEF-UCB Announces EU Regulatory Filing For Bimekizumab July 18 (Reuters) - Ucb SA UCB.BR : UCB ANNOUNCES EU REGULATORY FILING FOR BIMEKIZUMAB FOR TREATMENT OF MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA REGULATORY FILING SUPPORTED BY DATA FROM TWO BIMEKIZUMAB PHASE 3 STUDIES IN HIDRADENITIS SUPPURATIVA SAFETY AND EFFICACY OF BIMEKIZUMAB IN HS HAV
U
Reuters - Il y a 3 mois

HSBC initiates 14 biopharma stocks at 'buy' amid sector headwinds

BUZZ-HSBC initiates 14 biopharma stocks at 'buy' amid sector headwinds ** HSBC initiates 14 biopharma stocks in Europe and the U.S. at "buy" based on their smaller exposure to exclusivity losses and pricing and regulatory pressures ** "The inflationary pressures in most of the world and political will to control drug prices are leading to the regul
A
B
G
L
N
P
R
S
S
U
Reuters - Il y a 3 mois

AstraZeneca, Novo Nordisk, Telefonica Deutschland

EUROPE RESEARCH ROUNDUP-AstraZeneca, Novo Nordisk, Telefonica Deutschland July 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Novo Nordisk and Telefonica Deutschland, on Friday. HIGHLIGHTS * AstraZeneca AZN.L : HSBC initiates coverage with buy rating * Bayer AG BAYGN.DE : HSBC initiates coverage with reduce rating * Genmab A/S GMAB.CO : HSBC initiates coverage with buy rating * Novo Nordisk NOVOB.CO : HSBC initiate
A
A
A
B
B
B
B
B
B
C
C
C
E
E
G
H
H
K
L
N
N
R
R
S
S
T
U
W
A
A
A
B
R
Reuters - Il y a 3 mois

UCB Announces US FDA Approval Of RYSTIGGO For Treatment Of Adults With Generalized Myasthenia Gravis

BRIEF-UCB Announces US FDA Approval Of RYSTIGGO For Treatment Of Adults With Generalized Myasthenia Gravis June 27 (Reuters) - UCB SA UCB.BR : UCB ANNOUNCES U.S. FDA APPROVAL OF RYSTIGGO® (ROZANOLIXIZUMAB-NOLI) FOR THE TREATMENT OF ADULTS WITH GENERALIZED MYASTHENIA GRAVIS Source text for Eikon: ID:nPn1X5wrwa Further company coverage: UCB.BR
U
Reuters - Il y a 3 mois

UCB falls after delay in US approval of psoriasis drug Bimzelx

BUZZ-UCB falls after delay in US approval of psoriasis drug Bimzelx ** Shares in UCB UCB.BR slip 2.4% after the Belgian drugmaker said its psoriasis treatment Bimzelx would likely not receive U.S. approval before Q3, after previously stating the FDA examination could occur in Q2 ** Analysts at ING see the news as "negative for the equity story", saying Bimzelx is a key element in UCB reaching its 2025 targets ** UCB reiterates its FY guidance ** "Based on our understanding ...
U
Reuters - Il y a 3 mois

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch June 27 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. ACCOR ACCP.PA : The hotel group said on Monday its stake in Risma to Mutris at the price of 130 Moroccan durhams ($13.08) per share. COFINIMMO COFB.BR : The Belgian real estate trust announced it has divested of its Woluwe 58 building and will move in 2024. SANOFI SASY.PA The Company released pha
A
C
S
U
U
Reuters - Il y a 3 mois

UCB Receives FDA Approval Of Rystiggo To Treat Adults With Generalized Myasthenia Gravis

BRIEF-UCB Receives FDA Approval Of Rystiggo To Treat Adults With Generalized Myasthenia Gravis June 27 (Reuters) - Ucb SA UCB.BR : UCB ANNOUNCES U.S. FDA APPROVAL OF RYSTIGGO[®] (ROZANOLIXIZUMAB-NOLI) FOR TREATMENT OF ADULTS WITH GENERALIZED MYASTHENIA GRAVIS ADDITIONAL TREATMENT OPTION PROVIDES OPPORTUNITY FOR U.S. CLINICIANS TO TAILOR THERAPEUTIC APPROACH BASED ON INDIVIDUAL PATIENT NEEDS ROZANOLIXIZUMAB-NOLI WILL BE COMMERCIALLY AVAILABLE IN U.S.
U
Reuters - Il y a 3 mois

UCB Says Biologics License Application For Bimekizumab Remains Under FDA Review

BRIEF-UCB Says Biologics License Application For Bimekizumab Remains Under FDA Review June 26 (Reuters) - Ucb SA UCB.BR : ANNOUNCED THAT BIOLOGICS LICENSE APPLICATION (BLA) FOR BIMEKIZUMAB FOR TREATMENT OF ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS REMAINS UNDER REVIEW WITH U.S. FOOD & DRUG ADMINISTRATION (FDA) UCB NOW ANTICIPATES FDA ACTION I
U
Reuters - Il y a 4 mois

UCB Receives New EC Approvals For Bimzelx (Bimekizumab)

BRIEF-UCB Receives New EC Approvals For Bimzelx (Bimekizumab) June 7 (Reuters) - Ucb SA UCB.BR : RECEIVES NEW EUROPEAN COMMISSION APPROVALS FOR BIMZELX (BIMEKIZUMAB) FOR TREATMENT OF PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS APPROVAL IN PSA IS SUPPORTED BY TWO PHASE 3 STUDIES WHERE BIMEKIZUMAB SHOWED IMPROVEMENTS VERSUS. PLACEBO EC APPROVAL I
U
Reuters - Il y a 4 mois

UCB: New Data On Bimekizumab In Psoriatic Arthritis And Axial Spondyloarthritis

BRIEF-UCB: New Data On Bimekizumab In Psoriatic Arthritis And Axial Spondyloarthritis May 31 (Reuters) - Ucb SA UCB.BR : NEW LONG-TERM DATA ON BIMEKIZUMAB IN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PRESENTED AT EULAR 2023 IN PATIENTS WITH PSORIATIC ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS, BIMEKIZUMAB DE
U

Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Nous utilisons des cookies pour vous donner la meilleure expérience possible de notre site internet. En savoir plus ou modifier vos paramètres de cookies.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques